Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in this application:

- Claim 1. (Currently amended) A pharmaceutical dosage form for use in a dry powder inhalation deviges which comprises:
 - (a) at least one micronized or spray dried solid active ingredient, which active ingredient is soluble in water; and
 - (b) a coating material selected from the group consisting of a fatty acid, an alcohol derivative and a poloxamer, wherein the coating material coats at least partially the surface of the active ingredient.
 - wherein the pharmaceutical dosage form has an average mass median aerodynamic diameter (MMAD) of 0.5 15 µm.
- Claim 2. (Original) The pharmaceutical dosage form as recited in claim 1 wherein the active ingredient has been encapsulated and the coating material partially coats the soencapsulated active ingredient.
- Claim 3. (Original) The pharmaceutical dosage form as recited in claim 1 further comprising a solid, pharmaceutically acceptable carrier excipient and the coating material coats at least partially the surface of the agglomerate or the mixture formed by the active ingredient and the carrier excipient.
- Claim 4. (Original) The pharmaceutical dosage form as recited in claim 1 wherein the active ingredient has a mean mass aerodynamic diameter of about 0.5 to about 8 µm.
- Claim 5. (Original) The pharmaceutical dosage form as recited in claim 1 wherein the coating material is a fatty acid sorbitan ester or a PEG ether thereof.
- Claim 6. (Original) The pharmaceutical dosage form as recited in claim 5 wherein the sorbitol derivative is selected from the group consisting of sorbitan mono-oleate, sorbitan trioleate, sorbitan monostearate, sorbitan tristearate, sorbitan monolaurate, sorbitan trilaurate, sorbitan monomyristate, sorbitan trimyristate, sorbitan monopalmitate, sorbitan tripalmitate, PEG sorbitan monolaurate, PEG sorbitan monopalmitate, PEG sorbitan mono-oleate and PEG sorbitan trioleate.